ABBVAbbVieRunning, no new patients
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 66 (final count)
- Started
- Oct 12, 2017
- Main results expected
- Dec 2030
- Fully finished
- Dec 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: Measured up to 2 years after the last participant has enrolled in the study.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02966756 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC